Clareo Health | A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)
A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
With
Xcenda, LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients aged ≥18 years at the time of riociguat treatment initiation
Diagnosis of PAH per National Institute for Health and Care Excellence (NICE) 2018 classification
Decision to initiate treatment with riociguat as per investigator's routine treatment practice made prior to enrollment in the study
Initiation of riociguat, as per the FDA-approved US label:
* At enrollment OR
* ≤90 days prior to enrollment, with a documented titration regimen (defined as all documented dose changes including, but not limited to: starting dose and dates and highest tolerated dose and dates)
Signed informed consent
You may not be if
Previously treated with and discontinued use of riociguat for any reason prior to study enrollment (discontinuation defined as an interruption of therapy ≥30 days)
Participating in any of the following:
1. Blinded clinical trial
2. Clinical trial involving an unapproved drug
3. Investigational program with interventions outside of routine clinical practice
Life expectancy \<12 months
Contraindicated to receive riociguat per the FDA approved US label
Use of nitrates or NO donors in any form
Use of PDE5 inhibitors
PH associated with idiopathic interstitial pneumonias
